On March 8, 2024, Novo Nordon’s logo was located in the office of Baggswad, a Bugswad of Copenhagen, Danish.
Tom Litel | Reuters
Shares Novo On Friday, the company’s stock price rose after the Danish pharmaceutical giant reported its early stage of the early stage of the early stage of Amgandine obese drugs.
The test shows that this treatment through injections will reduce the weight of obesity and overweight patients by 22%after 36 weeks. In contrast, patients who were treated with placebo during the same period increased by 2.0%.
The stock price closed up 7.13%, and the increase of nearly 14% earlier, but it still recorded the best single -day performance since March 2024.
Danish obese drug manufacturer’s stock New Zealand Pharmaceutical Company It also risen by 4.7%, and Zepbound-Maker Lili Lili Company The trading before the market has declined.
The target of insulinin is the same as the intestinal hormone (GLP-1) imitated by Wegovy, as well as the amylin pancreatic hormone that affects hunger. Wegovy is the flagship obesity drug of Novo and Nord, while Ozempic is its diabetic therapy drug.
The test is based on 125 overweight or obesity patients. The most common side effects are gastrointestinal side effects. Most side effects are “mild to moderate severity.”
Martin Lange, the executive vice president of Nuo and Nord, said in a statement: “We are very encouraged by the results of the subcutaneous 1b/2A in the subcutaneous 1b/2A in the hyper heavy or obese people.”
“The results in the experiment support the potential of this new single-molecular GLP-1 and insulin receptor agonist insulin. We have seen this potential in oral preparations before.”
Novo is also developing an Amyretin weight loss pill. Early trial It was announced in September that an average weight decreased by 13.1%after 12 weeks. The company said at the time that this treatment was safe and tolerant for patients, but there was a mild to moderate side effects.